Fibronostics has announced the completion of its acquisition of Stone Clinical Laboratories, LLC, based in New Orleans, Louisiana. The transaction was finalized on October 27, 2025.
Stone Clinical Laboratories is a leading provider of advanced laboratory services in the United States. The company specializes in preventative and molecular diagnostics testing supported by a customer-focused boutique service.
Fibronostics is a global health technology company specializing in non-invasive diagnostic solutions for chronic diseases, with a focus on liver and metabolic disorders. Its flagship platform, LIVERFASt®, enables clinicians to assess liver health quickly and at scale. The company partners with global pharmaceutical firms, diagnostic laboratories and healthcare systems to advance liver diagnostics and improve patient outcomes worldwide.
This strategic acquisition strengthens Fibronostics’ research and development position and reinforces its commitment to innovation in metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease.
Stone Clinical Laboratories brings technical expertise and testing capabilities that complement Fibronostics’ proprietary digital health platforms, including LIVERFASt®. Together, they will advance biomarker development, R&D programs and clinical validation studies supporting therapeutic innovation and patient management. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the 102nd Laboratories, MRI and Dialysis transaction of the year, and the 33rd in the laboratories subsector. Throughout all of 2024, there were 121 Laboratories, MRI and Dialysis transactions, 40 of them in the laboratories subsector.
